Comparative Pharmacology
Head-to-head clinical analysis: GANTRISIN versus SULMEPRIM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GANTRISIN versus SULMEPRIM.
GANTRISIN vs SULMEPRIM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive inhibitor of dihydropteroate synthase, blocking para-aminobenzoic acid (PABA) incorporation into dihydropteroic acid, thereby inhibiting bacterial folate synthesis and nucleic acid production.
Sulmeprim is a combination of sulfamethoxazole, a sulfonamide, and trimethoprim, a dihydrofolate reductase inhibitor. It inhibits sequential steps in bacterial folate synthesis, leading to bactericidal activity.
2-4 g orally initially, then 4-8 g daily in 3-6 divided doses
Adults: 800 mg sulfamethoxazole/160 mg trimethoprim (one double-strength tablet) orally every 12 hours for 10-14 days. For severe infections or pneumonia, intravenous dose: 15-20 mg/kg/day (based on trimethoprim component) divided every 6-8 hours.
None Documented
None Documented
7-12 hours (mean 10 hours); prolonged to 20-50 hours in renal impairment (CrCl <30 mL/min)
Terminal elimination half-life is 10-12 hours in patients with normal renal function, allowing twice-daily dosing. In severe renal impairment (CrCl <30 mL/min), half-life extends to >20 hours, requiring dose adjustment.
Renal: 70% as unchanged drug; hepatic metabolism: 30% as acetylated metabolites; biliary: <3%
Renal excretion of unchanged drug accounts for 70% of elimination; 20% is metabolized in the liver to inactive metabolites (glucuronide conjugates) and excreted in urine; 10% is eliminated in feces via biliary excretion.
Category C
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic